Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.78 |
| ▸ | GAA | P10253 | 1/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.78 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.78 |
| ▸ | TYR | P14679 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | AHR | P35869 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28265079 | 0.92 | USP2 (0.66) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL29440252 | 0.88 | USP2 (1.00) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL50566 | 0.88 | USP2 (1.00) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL4542260 | 0.88 | USP2 (0.70) | USP2GAAALOX15RAD51NPSR1 | |
| Water SCHEMBL28220544 | 0.86 | USP2 (0.95) | USP2GAAALOX15RAD51NPSR1 | |
| Bromide SCHEMBL6029763 | 0.86 | USP2 (0.95) | USP2GAAALOX15RAD51NPSR1 | |
| Hydrochloric Acid SCHEMBL4718421 | 0.86 | USP2 (0.95) | USP2GAAALOX15RAD51NPSR1 | |
| Acetic Acid SCHEMBL23646038 | 0.85 | TYR (0.78) | USP2GAAALOX15RAD51NPSR1 | |
| Acetaldehyde SCHEMBL308459 | 0.85 | USP2 (0.78) | USP2GAAALOX15RAD51NPSR1 | |
| Trifluoroacetic Acid SCHEMBL30029434 | 0.84 | USP2 (0.70) | USP2GAAALOX15RAD51NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 764 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719497-A1 | METHODS FOR TREATING SSTR POSITIVE CANCER | Rayzebio, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20250228842-A1 | USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF CARCINOID SYNDROME | Crinetics Pharmaceuticals, Inc. | 2025-07-17 | — | — | US | claimed |
| US-20250041363-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ALCOHOL USE DISORDER AND ALCOHOL-ASSOCIATED LIVER DISEASE | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2025-02-06 | — | — | US | claimed |
| WO-2024249352-A1 | METHODS FOR TREATING SSTR POSITIVE CANCER | RAYZEBIO, INC. (US) | 2024-12-05 | — | — | WO | claimed |
| EP-4463159-A1 | USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF CARCINOID SYNDROME | Crinetics Pharmaceuticals, Inc. (US) | 2024-11-20 | — | — | EP | claimed |
| CN-112946150-B | Method and kit for rapidly detecting homovanillic acid, vanilla mandelic acid, 5-hydroxy indoleacetic acid and creatinine in human urine | 深圳华大临床检验中心 | 2024-06-18 | — | — | CN | claimed |
| WO-2023137018-A1 | USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF CARCINOID SYNDROME | Crinetics Pharmaceuticals, Inc. (US) | 2023-07-20 | — | — | WO | claimed |
| CN-114828648-A | Pet food compositions | 希尔氏宠物营养品公司 | 2022-07-29 | — | — | CN | claimed |
| WO-2021221591-A1 | SYSTEM AND METHOD MEASURING GLUCOSE FROM URINE | ERKEN HAYDAR ALI (TR) | 2021-11-04 | — | — | WO | claimed |
| US-20210198612-A1 | APPARATUS FOR ENRICHING AND SCREENING TARGET OBJECT SUCH AS CELL, BACTERIA OR BIOMOLECULE FROM SAMPLE | SUZHOU BIOFLUX MEDICAL TECHNOLOGY LTD. (CN) | 2021-07-01 | — | — | US | claimed |
| US-20050181065-A1 | Pharmaceutical composition inducing cancer cell differentiation and the use for treatment and prevention of cancer thereof | BIO GRAND CO., LTD. (TW) | 2005-08-18 | — | — | US | claimed |
| US-20040131595-A1 | Treating carcinoid neoplasms with therapeutic viruses | WELLSTAT BIOLOGICS CORPORATION | 2004-07-08 | — | — | US | claimed |
| WO-2004043222-A2 | TREATING CARCINOID NEOPLASMS WITH THERAPEUTHIC VIRUSES | WELLSTAT BIOLOGICS CORPORATION (US) | 2004-05-27 | — | — | WO | claimed |
| EP-0964875-B1 | 5-HYDROXYTRYPTOPHOL (5-HTOL) DERIVATIVES, ANTIBODIES, IMMUNOASSAYS AND DETECTION OF RECENT ALCOHOL CONSUMPTION | ALCO DIA AB (SE) | 2004-03-03 | — | — | EP | claimed |
| EP-1051179-A2 | ANTI-ESTROGEN PLUS PROGESTIN CONTAINING ORAL CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-15 | — | — | EP | claimed |
| EP-0964875-A1 | 5-HYDROXYTRYPTOPHOL (5-HTOL) DERIVATIVES, ANTIBODIES, IMMUNOASSAYS AND DETECTION OF RECENT ALCOHOL CONSUMPTION | Axis Biochemicals ASA (NO) | 1999-12-22 | — | — | EP | claimed |
| WO-1999024027-A2 | ANTI-ESTROGEN PLUS PROGESTIN CONTAINING ORAL CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-05-20 | — | — | WO | claimed |
| WO-1998024819-A1 | 5-HYDROXYTRYPTOPHOL (5-HTOL) DERIVATIVES, ANTIBODIES, IMMUNOASSAYS AND DETECTION OF RECENT ALCOHOL CONSUMPTION | AXIS BIOCHEMICALS ASA (NO) | 1998-06-11 | — | — | WO | claimed |
| EP-0006792-B1 | IODINATED COMPOUND USABLE AS RADIO-IMMUNOLOGICAL TRACER AND ITS PROCESS OF PREPARATION | COMMISSARIAT A L'ENERGIE ATOMIQUE Etablissement de Caractère Scientifique Technique et Industriel (FR) | 1982-06-23 | — | — | EP | claimed |
| US-4331646-A | Iodine compound for use as a tracer in radioimmunology | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1982-05-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228842-A1 | USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF CARCINOID SYNDROME | SSTR4, SSTR5, SSTR2 | USP2 2056/4885GAA 1778/4885ALOX15 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.